Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | GSK3A | P49840 | 3/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672350 | 0.90 | GSK3B (0.51) | GSK3BMAPTALDH1A1GAAMEN1 | |
| SCHEMBL4675036 | 0.88 | GSK3B (0.51) | GSK3BMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL7026093 | 0.87 | GSK3B (0.63) | GSK3BMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL5082188 | 0.86 | GSK3B (0.54) | GSK3BMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL5082606 | 0.85 | GSK3B (0.55) | GSK3BMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL5092333 | 0.83 | GSK3B (0.59) | GSK3BMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL14175422 | 0.83 | GSK3B (0.64) | GSK3BMAPTMEN1KMT2AGSK3A | |
| SCHEMBL5089359 | 0.82 | GSK3B (0.56) | GSK3BMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL4393590 | 0.82 | GSK3B (0.84) | GSK3BMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL6084866 | 0.82 | GSK3B (0.84) | GSK3BMAPTNPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060135534-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135534-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, GSKIP | GSK3B 1/4885MAPT 190/4885NPC1 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.